Company intelligence / Profile preview

3D Imaging Drug Design

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

3D Imaging Drug Design is an Australian biotechnology company focused on the development of novel radiopharmaceuticals and small molecule therapeutics for oncology. The company leverages advanced structure-based drug design and molecular imaging technologies to create targeted agents that can both diagnose and treat various cancers. Their primary research efforts are centered on high-value targets such as Prostate-specific membrane antigen (PSMA) and Fibroblast activation protein (FAP). By integrating 3D imaging into the drug discovery process, the company aims to improve the precision and efficacy of cancer treatments.

Therapeutic areas: Oncology
Modalities: Small moleculeRadiopharmaceutical
Industry: Biotech

Partnerships

University of SydneyANSTO

Beyond the preview

Go deeper on 3D Imaging Drug Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D Imaging Drug Design.

Explore the full profile